Antisense and RNAi Therapeutics Market Set for Rapid Growth, to reach Value around US$ 3.06 Bn. by 2029
Zion Market Research has published a new report titled “Antisense and RNAi Therapeutics Market by Technology (RNAi [miRNA, and siRNA], and Antisense RNA), by Route of Administration (Pulmonary, Intravenous, Intra-Dermal, Intra-Peritoneal, Topical, and Others), and by Indication (Oncology, Cardiovascular Diseases, Renal Diseases, Neurodegenerative Diseases, Respiratory Diseases, Genetic Diseases, Infectious Diseases, and Other Disease Indications): Global Industry Perspective, Comprehensive Analysis and Forecast.
According to the report, global demand for Antisense and RNAi Therapeutics Market was valued at US$ 1.47 Bn. in 2022 and is expected to reach US$ 3.06 Bn. by 2029, at a CAGR of 11% during the forecast period of 2022 to 2029.
Antisense is a technology that includes the synthesis of nucleic acid strands which bind to the splicing site or mRNA on the pre-mRNA and inactivates it efficiently. It is a very predominant technology used by researchers, and pharma-biotech companies for numerous applications like research, diagnostics, and therapeutics. RNAi therapeutics has vast scope in the treatment of cancer and neurodegenerative disorders. For treatment of rare and serious chronic diseases RNAi and antisense therapeutics are novel therapeutic options.
The market for antisense and RNAi therapeutics is mainly driven by the increasing cancer cases worldwide. Moreover, collaborations between pharma and biotech companies, technological advancements are also increasing. Besides, quick commercialization of pipeline therapeutics is also providing competitive edge to the market with multifactorial disease targeting which is likely to open new avenues for antisense and RNAi therapeutic market. However, high expenditure on research, threat of failure, and hurdles in drug delivery systems are the some of the factors restraining market growth.
The market for antisense and RNAi therapeutics is segmented based on indication, technology, route of administration, and regions. The market is segmented on the basis of technology into antisense RNA, and RNAi. The RNAi technology is further segmented into siRNA, and miRNA. The segment for antisense RNA held major share of the market due to its potential usage in therapeutics. Moreover, these molecules are also tested for the prevention of diseases onset and also to halt disease progression. On the basis of route of administration the market is segmented into topical, intra-peritoneal, intra-dermal, pulmonary, intravenous, and other delivery methods. Scientists in this field are developing new delivery systems like nanocarriers, in order to promote in-vivo delivery of oligonucleotides.
On the basis of indication the market for antisense and RNAi therapeutics is segmented into neurodegenerative diseases, respiratory diseases, cardiovascular diseases, genetic diseases, oncology, renal diseases, infectious diseases, and other disease indications. The segment for oncology held major share of the market owing to large number of research grants and licensing revenue which are associated with cancer-based trials for RNAi and antisense therapeutics.
Regional segmentation includes the current and forecast demand for Asia Pacific, North America, Latin America, Europe, and Middle East & Africa with its further bifurcation into major countries. North America held major share of the market in 2018, owing to increasing number of clinical trials that is supporting the process of initiation for developing antisense therapeutics and huge number of government policies supporting them in this region.
Some of the key players in antisense and RNAi therapeutic market -
- miRagen Therapeutics
- Isis Pharmaceuticals
- Santaris
- Antisense Therapeutics
- Alnylam Pharmaceuticals
- Silence Therapeutics.
This report segments the global antisense and RNAi therapeutics market as follows:
Global Antisense and RNAi Therapeutics Market: Technology Segment Analysis
- RNAimiRNAsiRNA
- Antisense RNA
Global Antisense and RNAi Therapeutics Market: Route of Administration Segment Analysis
- Pulmonary
- Intravenous
- Intra-dermal
- Intra-peritoneal
- Topical
- Other
Global Antisense and RNAi Therapeutics Market: Indication Segment Analysis
- Oncology
- Cardiovascular Diseases
- Renal Diseases
- Neurodegenerative Diseases
- Respiratory Diseases
- Genetic Diseases
- Infectious Diseases
- Other Disease Indications
Global Antisense and RNAi Therapeutics Market: Region Segment Analysis
- North AmericaU.S.
- EuropeUKFranceGermany
- Asia PacificChinaJapanIndia
- Latin AmericaBrazil
- Middle East and Africa
About Us:
Zion Market Research is an obligated company. We create futuristic, cutting-edge, informative reports ranging from industry reports, the company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us — after all — if you do well, a little of the light shines on us.
Contact Us:
Zion Market Research 244 Fifth Avenue, Suite N202 New York, 10001, United States Tel: +49–322 210 92714 USA/Canada Toll-Free №1–855–465–4651 Email: sales@zionmarketresearch.com Website: https://www.zionmarketresearch.com